an HCV− kidney, which might never come. Studies have demonstrated that HCV-infected candidates experience a survival benefit from KT 7, 15, 16 and have reduced waiting times when accepting HCV+ kidneys. 14, 17 At the same time, the therapy available for HCV treatment has improved. In the past, HCV treatment required PEGylated interferon (IFN), which was associated with low rates of sustained virologic response and high rates of kidney injury, rejection, and graft loss among KT recipients. [18] [19] [20] IFN-free direct-acting antiviral (DAA) combinations for HCV are now widely available, well tolerated, and have cure rates greater than 95%, including among ESRD patients and KT recipients. [21] [22] [23] [24] [25] In December 2013, 2 FDA-approved DAAs (sofosbuvir and simeprevir) were available and allowed providers to prescribe DAA curative regimens for patients. Since then, more than 8 distinct DAA regimens have been FDA-approved and made available for use. 26 Although the decision to treat HCV+ ESRD patients pretransplant or posttransplant remains controversial, [27] [28] [29] [30] these therapeutic breakthroughs might have changed clinical practice with respect to HCV+ kidneys. Finally, HCV+ deceased donors are now younger and healthier, 31 a change likely driven by the drug overdose epidemic. 32, 33 We hypothesized that DAA availability, coupled with improving quality of HCV+ donors, might have influenced practices related to HCV+ donor kidneys. We used national registry data to characterize changes in willingness to accept, utilization, discard, and posttransplant outcomes associated with HCV+ donor kidneys in the era of highly effective IFN-free DAAs.
MATERIALS AND METHODS

Data Sources
This study used data from the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system includes data on all donor, waitlisted candidates, and transplant recipients in the United States, submitted by the members of the Organ Procurement and Transplantation Network (OPTN), and has been described elsewhere. 34 The Health Resources and Services Administration, U.S. Department of Health and Human Services provides oversight to the activities of the OPTN and SRTR contractors.
Study Population
We identified 442501 adult (≥18) kidney transplant candidates listed between January 1, 2005, and March 2, 2018, of whom 18936 (4.3%) were willing to accept HCV+ donor kidneys. To characterize receipt of HCV+ kidneys, we identified 11409 adult HCV-antibody positive (HCV+) deceased donor kidney transplant (DDKT) recipients of whom 3348 (29.4%) had been transplanted with an HCV+ donor kidney between January 1, 2005, and March 2, 2017. To compare changes in practice before and after the introduction of IFN-free DAAs, hereafter referred to as DAAs, we defined 2 eras (IFN era: January 1, 2005 to December 5, 2013 vs DAA era: December 5, 2013 to March 2, 2018). We compared characteristics of candidates willing to accept HCV+ kidneys and of HCV+ recipients of HCV+ kidneys in each era using χ 2 tests for categorical variables and Wilcoxon rank-sum tests for continuous variables. HCV+ recipients with missing donor HCV (n = 4) were excluded.
Changes in Willingness to Accept HCV+ Kidneys and Receipt of HCV+ Kidneys
We used multilevel logistic regression to determine whether candidates were more likely to list as willing to accept HCV+ kidneys in the DAA versus IFN era, adjusting for candidate age, sex, race, diagnosis, insurance, and time on dialysis. We used multilevel logistic regression to determine whether HCV+ recipients were more likely to have received an HCV+ kidney in the DAA versus IFN era, adjusting for recipient age, sex, race, diagnosis, insurance, and time on dialysis. The multilevel logistic regression models include a random intercept for center, thereby allowing underlying rates of listing and HCV+ kidney utilization to vary across centers. The changes observed in the recent era can be interpreted as independent of center-level variation. To determine whether observed changes in willingness or receipt of HCV+ kidneys in the DAA era were beyond what we would expect given existing trends, we modeled listing and utilization as a function of time and used spline terms to determine whether there was a statistically significant change in existing trends after the introduction of DAAs.
Changes in Center-Level Use of HCV+ Kidneys
To determine whether an increase in use of HCV+ kidneys was driven by a few aggressive centers or occurring across centers, we identified 173 kidney transplant programs that had performed at least 1 transplant per year over the study period and that were not pediatric centers (defined as performing >70% pediatric transplants). To estimate center-level clustering of HCV+ to HCV+ kidney transplants, we calculated the Gini coefficient per era, a dimensionless statistic between 0 and 1 that indicates clustering. In the context of this study, a Gini coefficient closer to 1 indicates that fewer centers performed the majority of HCV+ to HCV+ kidney transplants.
Posttransplant Outcomes Associated With HCV+ Kidneys
We identified 121480 adult DDKT recipients transplanted between January 1, 2005, and July 31, 2017, and used Cox proportional hazards regression to estimate changes in posttransplant mortality associated with HCV+ deceased donor kidneys in the recent era. We tested the interaction between era and donor HCV status to characterize changes in the recent era that were above and beyond any changes observed overall among DDKT recipients. The final model was adjusted for recipient age, sex, race, time on dialysis, diagnosis, insurance, previous malignancy, vascular disease, panelreactive antibody status, transplant type, HLA mismatch, and body mass index (BMI), and donor age, sex, race, BMI, cause of death, increased infectious risk, hypertension, diabetes, creatinine, regional sharing, cold ischemia time, prerecovery diuretics, hepatitis B virus, lung infection, history of cancer, cigarette use, and donation after circulatory death.
Changes in Quality and Discard of HCV+ Kidneys
To characterize changes in quality (determined using Kidney Donor Profile Index [KDPI] ) and discard (defined as recovered and not transplanted) of HCV+ kidneys, we identified 195202 deceased donor kidneys recovered between January 1, 2005, and March 2, 2018, of which 8088 (4.14%) were recovered from HCV+ donors. We estimated the crude and adjusted relative rates of discard of HCV+ kidneys using modified Poisson regression accounting for clustering at the Donation Service Area level. The crude relative rate indicates the proportion of the HCV+ kidneys that were discarded relative to the proportion of HCV− kidneys that were discarded, while the adjusted relative rate accounts for changes in donor quality occurring among HCV+ deceased donors. 31 The final model was adjusted for donor age, race, sex, increased-infectious risk, BMI, donation after circulatory death, cause of death, blood type, creatinine greater than 1.5, history of hypertension, and history of diabetes. 35 To determine whether the association between HCV status and discard changed in the recent era, we tested the interaction between donor HCV and era. Deceased donors with missing or unknown HCV antibody status (0.1%) or missing BMI (0.43%) were excluded.
Sensitivity Analysis
The first line of DAAs, introduced in December 2013, were contraindicated for renal transplant candidates. To determine whether inferences were dependent on this definition, we performed a sensitivity analysis and estimated the odds of having received an HCV+ kidney in the era of FDA-approved DAA therapy (after October 1, 2014) among HCV+ recipients.
Statistical Analysis
Confidence intervals were reported according to the method of Louis and Zeger. 36 Analyses were performed using Stata 14.2/MP for Windows (College Station, TX). We used a 2-sided α of 0.05 to indicate a statistically significant difference.
RESULTS
Willingness to Accept HCV+ Kidneys
The number of incident candidates listed as willing to accept an HCV+ kidney increased from 1308 in 2005 (4.6% of incident candidates) to 2756 (7.8%) in 2017 ( Figure 1A ). In the IFN and DAA eras, 3.3% and 6.1% of candidates listed as willing to accept HCV+ kidneys, respectively. After accounting for center variation and candidate characteristics, candidates listed in the DAA era were 2.2 times more likely to list as willing to accept HCV+ kidneys than those listed in the IFN era (adjusted odds ratio [aOR], 2.07 2.23 2.41 ; P < 0.001). After modeling the trend as a function of calendar time, the per-year increase observed in the DAA era was marginally higher than expected given the trend observed between 2010-2013 (per-year increase from 2010-2013: 1.17 1.21 1.24 and from 2013-2018: 1.23 1.25 1.28 ; P value of interaction between spline terms = 0.047). Candidates listed as willing to accept HCV+ kidneys in the DAA era had slightly higher estimated posttransplant survival score (EPTS) scores at listing, were more likely to be female, more likely to be white, more likely to have diabetes, and slightly less likely to have been on dialysis (Table 1A) .
Use of HCV+ Kidneys for HCV+ Recipients
The number of HCV+ recipients who received HCV+ kidneys increased from 154 in 2005 (20.4% of HCV+ recipients) to 384 in 2017 (38.6%) ( Figure 1B ). In the IFN and DAA eras overall, 24.4% and 38.3% of HCV+ recipients were transplanted with HCV+ kidneys, respectively.
After accounting for center variation and recipient characteristics, HCV+ recipients transplanted in the DAA era were 1.95 times more likely to have received an HCV+ kidney than those in the IFN era (aOR, 1.76 1.95 2.16 ; P < 0.001). After modeling the trend as function of time, the per-year increase observed during the DAA era was statistically significantly higher than expected given the 2010 to 2013 trend (per year increase from 2010 to 2013: 0.91 0.99 1.07 and from 2013 to 2018: 1.07 1.15 1.23 ; P value of interaction between spline terms = 0.006). HCV+ recipients of HCV+ kidneys in the DAA era had higher EPTS scores, were older, more likely to be female, more likely to be white, more likely to have diabetes, and less likely to have been on dialysis (Table 1B) .
Center-Level Use of HCV+ Kidneys for HCV+ Recipients
Among the 173 transplant centers, all had performed at least 1 transplant among an HCV-infected recipient, 146 (84.3%) had performed at least 1 HCV+ donor to HCV+ recipient DDKT, and 106 (61.3%) used HCV+ kidneys among more than 20% of their HCV+ recipients over the study period. Ninety-three (53.8%) centers increased, 29 (16.7%) had no change in the percent, and 51 (29.5%) decreased the percent of HCV+ recipients transplanted with HCV+ kidneys in the DAA era ( Figure 2 ). Centers that increased the use of HCV+ kidneys in the DAA FIGURE 1. Percent of (A) incident kidney transplant candidates who were willing to accept an HCV+ kidney and (B) HCV+ kidney transplant recipients who received an HCV+ kidney; 2005-2018. era had similar annual DDKT volume to centers that decreased use (median annual DDKT of 52 vs 51 , respectively) and a slightly higher percent of recipients that were HCV-antibody positive (median HCV+ recipient prevalence 6.0% [4.1-7.6] vs 4.8% [3.2-7 .0], respectively). Of the 106 centers that used HCV+ kidneys for greater than 20% of HCV+ recipients, 65 centers (61%) increased and 41 (38.7%) decreased HCV+ kidney use in the DAA era.
Clustering of HCV+ to HCV+ transplants was highly localized within a subset of centers in both the IFN and DAA eras (Gini coefficients, IFN era 0.68 vs DAA era, 0.69). In the IFN era, 43 (24.9%) of the 173 centers performed 75% of the HCV+ to HCV+ transplants, and in the DAA era, 39 (22.5%) of the 173 centers performed 75% of the HCV+ to HCV+ transplants. For reference, 86 centers (49.7% of 173) performed 75% of the total number of DDKTs (irrespective of HCV) over the study period (Gini = 0.36).
Posttransplant Outcomes Associated With HCV+ Kidneys
Among HCV+ recipients, receiving an HCV+ deceased donor kidney was associated with 1.19-fold higher mortality when compared to receiving an HCV− kidney (aHR, 1.07 1.19 1.32 ). This 19% increased risk translated to 1-year survival of 94.9% and 95.3% for HCV+ recipients of HCV+ and HCV− kidneys, respectively (Figure 3) . Threeyear survival was 86.9% and 88.4% for HCV+ recipients of HCV+ and HCV− recipients. The risk associated with being an HCV+ recipient (1.36-fold higher mortality when compared with HCV− recipients [aHR, 1.28 1.36 1.46 ]) and the risk associated with receiving an HCV+ kidney were not statistically significantly different in the recent era (P value of interaction terms = 0.07 and 0.08, respectively).
Quality of HCV+ Kidneys
The prevalence of HCV among kidney donors increased In an unadjusted model, HCV+ kidneys were 3.1 and 2.4 times more likely to be discarded than HCV− kidneys 3.76 ; P < 0.001) ( Figure 5B ). After 2013, the unadjusted relative rate decreased to a 2.1-fold higher rate in the 2017 (RR, 1.89 2.08 2.29 ; P < 0.001).
After adjustment, HCV+ kidneys were 3.0 and 3.7 times more likely to be discarded than comparable HCV− kidneys in the IFN (adjusted relative rate [aRR], 2.78 3.02 3.27 ; P < 0.001) and DAA eras (aRR, 3.36 3.67 4.02 ; P < 0.001): a statistically significant increase (P value of the interaction<0.001). In 2014, HCV+ kidneys were 3.99 times more likely to be discarded than comparable HCV− kidneys (aRR, 3.50 3.99 4.54 ; P < 0.001). The relative rate declined slightly in 2017, such that HCV+ kidneys were 3.38 times more likely to be discarded than comparable HCV− kidneys (aRR, 2.96 3.38 3.87 ; P < 0.001).
Sensitivity Analysis
We found that HCV+ recipients transplanted after the introduction of FDA-approved DAAs were 2.0 times more likely to have received an HCV+ kidney than those transplanted before (aOR, 1.81 2.01 2.23 ; P < 0.001). These findings were consistent with the original analysis.
DISCUSSION
In this national registry study, we characterized changes in the use of HCV+ kidneys for HCV+ recipients after the introduction of DAA therapy. In the recent DAA era, candidates were 2.2 times more likely to list as willing to accept HCV+ kidneys, and HCV+ recipients were 1.95 times more likely to have been transplanted with an HCV+ kidney. Although 54% of transplant centers increased the use of HCV+ kidneys in the DAA era, the practice remained highly concentrated within a few centers. In the DAA era, 22.5% of centers performed 75% of HCV+ to HCV+ transplants, with no improvement since the IFN era. Discard of HCV+ kidneys decreased from 52.3% in the IFN era to 42.8% in the DAA era; however, after adjustment for donor characteristics, the relative rate of discard of HCV+ kidneys actually increased from a 3.0-fold higher rate in the IFN era to a 3.7-fold higher rate in the DAA era. Finally, posttransplant mortality associated with HCV+ kidneys (1.19-fold higher risk) remained unchanged in the recent era, although this translated to a 1.5% difference in survival between HCV+ recipients of HCV+ and HCV− kidneys 3 years posttransplant.
Possible explanations for the increasing willingness to accept HCV+ kidneys include increased prevalence of HCV infection among patients with ESRD, shorter waiting times for candidates who accepted HCV+ kidneys, 14, 17, 37 and the introduction of DAAs, which could be used to cure HCV infection after transplant. Although we observed an increase in willingness to accept HCV+ kidneys in the DAA era, it is important to note that the trend began before the introduction of IFN-free DAA therapy. The increase we observed in 2011 might have been driven by the introduction of telaprevir, the first DAA used in combination with IFN which foreshadowed the IFN-free DAA era. The increased availability of HCV-infected deceased donor organs driven by the opioid overdose epidemic might have also contributed to increased willingness. 33 Our finding that willingness decreased from 2005 to 2009 was consistent with the only other study on willingness to accept HCV+ kidneys. 38 In this study, Massie et al 38 also observed homogeneity in willingness to accept HCV+ kidneys within centers, and thus it might be possible that the increase was not driven by individual decision making, but by shifts in centerwide protocols.
We report that HCV+ recipients transplanted in the recent era were more likely to receive an HCV+ kidney than those transplanted during the IFN era. Possible explanations might include the improving quality of HCV+ kidneys driven by the opioid overdose epidemic, 33 the increasing prevalence of HCV in the deceased donor pool (from 3.6% in 2005 to 5.6% in June 2017), evidence of acceptable posttransplant outcomes associated with HCV+ kidneys, 17, 39 survival benefit associated with transplantation, 7, 15, 16 and the availability of DAA therapy. Recent changes to allocation policy might have increased the prioritization of HCV-infected recipients willing to accept HCV+ kidneys, leading to an increase in the proportion that were transplanted with HCV+ kidneys. However, we saw no significant changes in the panel reactive antibody of recipients of HCV+ kidneys in the recent era.
Center utilization of HCV+ kidneys remained highly clustered during the DAA era. While 54% of centers increased use of HCV+ kidneys, only 39 (22.5%) of 173 centers performed 75% of the total of HCV+ to HCV+ transplants in the DAA era. Kucirka et al 14 found similar clustering of HCV+ kidney to HCV+ recipient transplants between 1995 and 2009, indicating minimal improvement in the spread of these transplants across programs.
Multiple studies have reported 2-to 6-fold higher rates of discard of HCV+ kidneys using modified Poisson regression and logistic regression models. 14, 35, [40] [41] [42] During the IFN era, HCV+ donors had higher KDPI driven by older age and additional comorbidities; discard of these organs was likely not only due to HCV infection but also related to overall poorer quality of the kidney. Although the percent of discarded HCV+ kidneys decreased from 52% in 2005 to 37.6% in 2017, the adjusted relative rate of HCV+ kidneys actually increased from a 3.0-fold higher rate to 3.7-fold higher rate of discard than comparable HCV− kidneys. This suggests that discard of HCV+ kidneys was driven by the presence of HCV infection. Concerns about posttransplant outcomes or a small increased risk of other infections, such as HIV, might also be driving increased discard in recent years. 43 Although we observed 19% higher risk of mortality among those who received an HCV+ kidney, this translated to a 1.5% percentage point difference in survival 3 years posttransplant. These findings are consistent with those of Kucirka et al 14 and Heo et al. 44 However, candidates with HCV+ are not faced with the decision to accept an HCV+ or HCV− kidney on the same day, in which the choice would be clear. Candidates are more likely to face the decision to accept an HCV+ kidney today or remain on dialysis, where risk of death is higher. These elevated rates of discard are concerning given the risk of death on dialysis that HCV+ patients face and the survival benefit of KT even when the donor possesses an increased risk of disease transmission. 8, 45 We report that 27 of 173 active centers performed zero HCV+ kidney to HCV+ recipient transplants in the DAA era, and yet, the median KDPI of discarded HCV+ kidneys was 64 indicating that 25% of these kidneys had a KDPI below 49. Low competition surrounding HCV-infected donor kidneys might be allowing participating centers to select optimal HCV+ kidneys while transplantable HCV+ kidneys are discarded. To maximize the use of HCV+ kidneys, 2 centers have completed pilot trials in which HCV-negative transplant candidates received an HCV+ kidney transplant with either DAA prophylaxis 46 or preemptive DAA treatment. 47 Although this approach is attractive, DAAs are expensive and access to DAAs for transplant recipients outside of clinical trials is uncertain. 48 A recent study from the United Kingdom showed that transplantation with DAAs was cost-neutral with continued hemodialysis after 5 years. 49 Thus, the use of HCV+ kidneys in HCV− recipients may prove cost-effective and become standard practice in the future. 50 In the meantime, maximizing utilization of HCV+ kidneys for HCV+ recipients could improve outcomes for HCV+ candidates.
The limitations of our study merit consideration. HCV antibody status of transplant candidates is not available through OPTN data, and thus, we used willingness to accept HCV+ kidneys to characterize waitlist behaviors with respect to HCV+ kidneys. The prevalence of willingness to accept HCV+ kidneys does not represent the prevalence of HCV infection among dialysis patients, and we also expect that HCV+ candidates willing to accept HCV+ kidneys were different from HCV+ candidates unwilling to accept them. Unfortunately, we were unable to make this distinction. However, the incident waitlist candidates willing to accept HCV+ kidneys indicate that there remains a growing and unmet need for HCV+ kidneys. We did not have access to recipient or donor HCV RNA status or treatment history, factors which might directly affect the decision to use an HCV+ kidney. 51 Without treatment history, it is likely that we underestimated the proportion of actively infected HCV + recipients who received HCV+ kidneys, because patients treated on the waitlist would still appear as HCV antibody positive in the OPTN data. We defined drug eras based on the availability of IFN-Free DAAs; however, it is important to note that studies demonstrating the safety and efficacy of DAAs in kidney transplant recipients were not published until later. Finally, we were limited in our ability to control for unmeasured confounding that might have been present in our model comparisons. More granular kidney-related factors, such as biopsy findings or cold ischemia time, were not available for adjustment in the discard analysis.
We observed encouraging increases in willingness to accept HCV+ kidneys and use of HCV+ in the era of DAA therapy. However, we also observed that the number of centers performing HCV+ kidney transplants remains low, and might be driving the disproportionately high discard rates of HCV+ kidneys, despite the otherwise high quality of these organs. Broader utilization of HCV+ kidneys could improve outcomes for HCV+ candidates and reduce unnecessary discard of high quality HCV+ kidneys.
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